Michael A. Metzger - 06 Jul 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Chief Executive Officer, Director
Signature
/s/ Michael A. Metzger
Issuer symbol
SNDX
Transactions as of
06 Jul 2022
Net transactions value
-$222,012
Form type
4
Filing time
08 Jul 2022, 17:51:10 UTC
Previous filing
07 Jul 2022
Next filing
11 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $95,757 +15,009 +85% $6.38 32,668 06 Jul 2022 Direct
transaction SNDX Common Stock Sale $316,307 -15,009 -46% $21.07 17,659 06 Jul 2022 Direct F1, F2
transaction SNDX Common Stock Options Exercise $638 +100 +0.57% $6.38 17,759 07 Jul 2022 Direct
transaction SNDX Common Stock Sale $2,100 -100 -0.56% $21.00 17,659 07 Jul 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -15,009 -100% $0.000000* 0 06 Jul 2022 Common Stock 15,009 $6.38 Direct F3
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -100 -100% $0.000000* 0 07 Jul 2022 Common Stock 100 $6.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 702,068 options to purchase shares of common stock that are vested and immediately exercisable and a total of 554,172 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $21.00 to $21.25.
F3 This option vests periodically upon the Issuer achieving certain milestones.